M&T Bank
ACRS icon

M&T Bank’s Aclaris Therapeutics ACRS Stock Holding History

M&T Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8K Buy
+10,088
New +$34K ﹤0.01% 1672

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

M&T Bank's ACRS Position: Q1 2026 in Review

M&T Bank opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 10,088 shares worth $37.8K. The stake represents ﹤0.01% of the portfolio and ranks #1672 among its holdings.

136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • M&T Bank held 10,088 shares of Aclaris Therapeutics worth $37.8K as of Q1 2026.
  • Aclaris Therapeutics was a new M&T Bank position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q1 2026, its #1672 holding.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.